Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

Sarepta Therapeutics TodaySRPTSarepta Therapeutics$21.56 +0.00 (+0.02%) 52-Week Range$18.30▼$173.25Price Target$70.76Add to WatchlistIn another tragic incident, Sarepta Therapeutics NASDAQ: SRPT saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute liver failure (ALF) after doctors treated them with ELEVIDYS. Sadly, the same thing happened three months ago. As a result, Sarepta has suspended shipments of ELEVIDYS for non-ambulat ...